Medication info
Janumet 50/500 mg

Janumet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204367 · Approved 2022.12.05 · Insurance code 653806220

Summary

Main use
Improves glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: In patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy, or in patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in type 2 diabetes

View approved original text

This medicine helps improve blood sugar control in patients with type 2 diabetes. The two components, sitagliptin and metformin, work together to enhance the blood sugar-lowering effect. Additionally, combining this medicine with dietary and exercise regimens allows for smoother blood sugar management. Through this, it plays a crucial role in maintaining stable blood sugar levels in patients. Ultimately, this medicine is effectively used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: In patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy, or in patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).

Precautions

This medicine aids in blood sugar control. However, during the course of treatment, severe allergic reactions may occur, so if skin rash, hives, or difficulty breathing develops, you should immediately stop taking this medicine and consult a doctor. Additionally, pancreatitis, a serious inflammation of the pancreas, can occur rarely, so symptoms such as abdominal pain, nausea, or vomiting should be reported to a doctor immediately. This medicine should not be used in patients with significantly reduced kidney function, acute heart disease, severe infection, or dehydration. Before and after undergoing tests with iodine contrast agents, the use of this medicine must be temporarily discontinued, and treatment should only be resumed once kidney function has been confirmed to be normal. It is safest for women who are pregnant or may become pregnant, and for nursing mothers, to avoid taking this medicine. This medicine can cause hypoglycemia, so special caution should be exercised when meal intake is irregular or insufficient, or when taken alongside other blood glucose-lowering agents. While taking this medicine, regular kidney function and blood tests should be conducted, and any unusual symptoms should be reported to healthcare professionals immediately. Additionally, consuming alcohol may increase the risk of side effects from this medicine, so it is advisable to avoid drinking while on this medication. In case of scheduled surgery, stop taking this medicine 48 hours prior, and only resume after confirming normal kidney function post-surgery. Elderly patients may experience decreased kidney function, thus requiring dosage adjustments and regular kidney function monitoring. Common side effects while taking this medicine may include diarrhea, headache, upper respiratory infections, although most are mild. Finally, in the case of an overdose of this medicine, you should visit a hospital immediately for appropriate treatment, as some ingredients can be removed by dialysis.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 22 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • acute kidney failure
  • decreased appetite
  • itching
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medicine in a tightly sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.